
IMS Institute charts the future course of commercial-operations automation
Cost-cutting will continue while marketplace demands a higher level of data quality from pharma
It’s well known that the pharma industry commercial practices—sales, marketing, market research and distribution—are changing in the face of healthcare reform and cost pressure. How that will play out over the next several years is the subject of a
At the same time, the growth of digitized healthcare information—especially through use of
The report notes a broad-based movement toward cloud-based applications, especially in customer relationship-management systems, multichannel marketing and social media. Cloud systems
On the bright side, IMS sees an extensive list of optimization tactics to apply, in the areas of data management, resource management, workflow automation and outsourcing:
Knowledge and data management
- Insourcing of strategically important knowledge areas
- Creation of Center of Excellence model to share learning and best practices
- Better analytics to improve performance of commercial teams
- Standardization of processes and metrics
- Harmonization and rationalization of business insights and performance indicators
Resource management
- Closed loop technology to enable commercial teams to adjust course and tactics rapidly
- Standardization of core back office processes across departments and countries
- Outsourcing
- Transfer of specific low value functions to third parties and the cloud
- Relocation of labor to lower costs countries
- Shift to a flexible resource model using cloud technologies and third party services
- Shifting infrastructure and hardware to the cloud when feasible
- Replacing internal systems with Software as a Service (SaaS) cloud applications
Workflow automation
- Restructuring of IT systems and processes to remove silos, overlap, and duplication
- Improving the flow of information between systems
- Centralization of systems such as data management, reporting, analytics, CRM
While there is a parallel effort going on in the R&D side of life sciences to reduce costs by better data automation and analytical tools, Murray Aitken, executive director of the Institute, tells Pharmaceutical Commerce that that area was not a focus of the study, but notes that it will be increasingly valuable in areas such as pharmacovigilance and patient support. It’s also worth noting that IMS Health itself (the parent of the Institute) is making moves away from its traditional role as a provider of pharma sales activity and commercial practices, and into healthcare generally, and IT services such as social media, CRM and related areas. The company, currently in a quiet period following the filing of paperwork for an anticipated IPO, is getting ready for the industry’s future state.
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.





